Paul Singer Biomarin Pharmaceutical Inc Transaction History
Elliott Investment Management L.P.
- $18.8 Billion
- Q3 2024
A detailed history of Paul Singer (Elliott Investment Management L.P.) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Elliott Investment Management L.P. holds 3,500,338 shares of BMRN stock, worth $217 Million. This represents 1.31% of its overall portfolio holdings.
Number of Shares
3,500,338
Previous 3,500,338
-0.0%
Holding current value
$217 Million
Previous $288 Million
14.62%
% of portfolio
1.31%
Previous 1.72%
Shares
2 transactions
Others Institutions Holding BMRN
# of Institutions
639Shares Held
178MCall Options Held
2MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.41 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.2 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.17 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$862 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$651 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.5B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...